Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.
The question comes up almost every time someone starts looking into our program. They have done their research, read something online, maybe heard something skeptical from a family member. Before anything else, they want to know: is compounded semaglutide safe, or is this something sketchy off the internet?
I never rush past that question. It deserves a direct answer. And the fact that I own a pharmacy that compounds medication means I can give one that most telehealth providers simply cannot.
The skepticism is warranted — and more warranted now than two years ago. The FDA has been active in this space. More than 55 warning letters went out to compounders and telehealth firms in 2025 alone. Major platforms have exited the compounded GLP-1 market entirely. There is a legitimate gray market for GLP-1 compounds operating completely outside any regulatory framework. What we do at Precision Telemed is nothing like that, and the difference is specific and verifiable.
What a 503A Compounding Pharmacy Actually Is
A 503A pharmacy is a licensed compounding pharmacy operating under state pharmacy board oversight and following the sterile compounding standards set by the United States Pharmacopeia, specifically USP Chapter 797. Congress created the 503A framework to allow licensed pharmacists to prepare customized medications for individual patients when commercially available products do not meet a specific clinical need. State boards have inspection authority. Pharmacists must meet licensure requirements. The facility must pass periodic inspections.
USP Chapter 797 establishes enforceable standards for sterile compounding — cleanroom design, environmental monitoring, personnel training, equipment qualification, sterility testing, beyond-use dating, and microbial contamination controls. These are not guidelines. They are the baseline a licensed facility must meet or face regulatory action.
Compounded semaglutide prepared under this framework has not been reviewed or approved by the FDA and is not the same as commercially available Ozempic or Wegovy. That distinction matters — it is not something to gloss over, and I don’t.
The Regulatory Landscape in 2025–2026: What Changed and What Didn’t
My pharmaceutical trade background means I follow regulatory developments in this space closely — and there has been significant change that anyone evaluating compounded GLP-1s deserves to understand.
The FDA declared the semaglutide shortage resolved in February 2025. The broad shortage-based pathway that had allowed 503A pharmacies to compound “essentially a copy” semaglutide at scale closed in April 2025. What did not close is the core 503A framework for patient-specific compounding, which permits a licensed prescriber to document that a compounded formulation produces a clinically significant difference for an individual patient — a dose strength not available in the commercial pen, for example. That is a narrower, more carefully documented practice than what operated during the shortage, and it is how legitimate 503A operations are functioning in 2026.
Why I Built the Pharmacy Myself
I evaluated third-party compounding partners early in building this business. I came away unimpressed more than once. My pharmaceutical background gave me a clear picture of what a quality system looks like and what it does not. I was not willing to build a telehealth practice on a supply chain I did not fully control — so I built a relationship with a 503A pharmacy that meets that standard, with ongoing compliance oversight baked into the model.
That was the harder path. It was also the only acceptable one from where I stood.
What Certificate of Analysis Testing Actually Verifies
Every batch of active pharmaceutical ingredient we use undergoes COA testing from an independent, accredited laboratory. A properly conducted COA for a pharmaceutical-grade compound includes identity testing by HPLC (confirming it is actually semaglutide, not a structural analog), potency testing (confirming concentration within acceptable tolerance), sterility testing (absence of viable microbial organisms), and endotoxin testing (bacterial endotoxin levels that could cause serious reactions if injected).
That is objective, third-party documentation that the medication is what it claims to be. I can show the COA for the batch any given patient’s medication was made from. That level of traceability does not exist when someone orders peptides from an unregulated website under a research-use-only disclaimer. The distinction is specific and large.
The Clinical Safety Record of the Active Molecule
Separate from the compounding question is the molecule itself. The STEP 2 trial enrolled adults with overweight or obesity and type 2 diabetes and demonstrated meaningful weight reduction with a well-characterized side effect profile (Davies et al., Lancet 2021, PMID 33667417). GI effects — nausea most prominently — were the dominant adverse events, dose-dependent, and improved over time for most patients.
The active molecule in compounded semaglutide is the same molecule studied in those trials. What changes with compounding is the inactive ingredients, the delivery device, and the price. What does not change is that compounded semaglutide has not been FDA-reviewed as a finished drug product. That is a meaningful difference from FDA-approved options, and our clinical team discusses it with every patient.
For more on the molecule itself, see How Semaglutide Works at a Cellular Level. For a direct comparison with brand-name Ozempic, see Is Compounded Semaglutide the Same as Ozempic?.
What to Ask Any Telehealth Provider
Anyone evaluating a telehealth provider offering compounded semaglutide should be able to get answers to these questions: Is the pharmacy 503A-licensed? Can they provide COA documentation? Where does their API come from? What sterile compounding standards are they following? What is the documented clinical basis for the compounded prescription for that specific patient?
These are not difficult questions for a legitimate operation. They are only difficult if the answers are unflattering.
FAQ
Q: Is compounded semaglutide FDA-approved? No. Compounded semaglutide is not FDA-approved as a finished drug product. It is prepared under the 503A compounding pharmacy framework, which is regulated through state pharmacy board oversight and USP Chapter 797 standards. It is not the same as commercially available FDA-approved semaglutide products.
Q: How is compounded semaglutide different from buying peptides online? They are completely different in regulatory status. Compounded semaglutide from a licensed 503A pharmacy requires a valid prescription, undergoes COA testing, and is subject to state board inspections. Peptides sold online without a prescription carry a research-use-only disclaimer and operate entirely outside pharmaceutical regulatory frameworks.
Q: What does a certificate of analysis tell me about my medication? A COA from an independent accredited laboratory confirms identity by HPLC, potency within acceptable tolerances, sterility, and endotoxin levels — objective third-party documentation of what the medication is and what it contains.
Q: Is it still legal to prescribe compounded semaglutide in 2026? Under the 503A patient-specific framework, yes — when a licensed prescriber documents a specific clinical reason the commercial product does not meet the patient’s individual need. The broad shortage-based pathway ended in April 2025. Patients should ask any provider to explain the clinical basis for a specific compounded prescription.
Q: How do I verify a telehealth provider is using a legitimate pharmacy? The pharmacy name, 503A license status, and COA documentation are all things a legitimate provider should be able to supply on request. Pharmacy license status can be verified through the relevant state pharmacy board website in a matter of minutes.
References
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed
If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.
This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.